Tailoring Natural Effector Functions: Antibody Engineering Beyond Humanization
A large number of new biological drugs in clinical development from the biotechnology industry are based on recombinant antibodies. The Food and Drug Administration (FDA) has recently approved several of these drugs including reagents against cancer (1 ,2 ), transplant rejection (3 ), rheumatoid arthritis, and Crohn’s diseases (4 ,5 ) as well as antiviral prophylaxis (6 ). At present 30% of all biological proteins in application for FDA approvals are recombinant antibodies. Some are based on fusions of murine variable regions with human constant region, called chimeric antibodies. Others are more sophisticated being “humanized” from their mouse monoclonal parent molecule, whereas more recently full human antibodies from phage antibody libraries have been generated (7 ).
- Polymerase Chain Reaction for Detection of the t(14;18) Translocation in Lymphomas
- Production of Plasmid DNA as a Pharmaceutical
- Gene Expression Profiling of Leukemia Stem Cells
- Treatment Strategies in Metastatic Renal Cell Carcinoma: Cytokines, Vaccines, and Gene Therapy
- Designing Adenoviral Vectors for Tumor-Specific Targeting
- Immunohistochemical Detection and Quantitation of Cell Surface Receptors for Prostanoids
- Determinants of Incidence of Primary Fallopian Tube Carcinoma (PFTC)
- 干細胞和衰老的終結(第四部分)
- Enrichment of Methylated DNA by Methyl-CpG Immunoprecipitation
- 細胞穩(wěn)定轉(zhuǎn)染建系后再轉(zhuǎn)染的問題